Know Cancer

forgot password

S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM)

Phase 2
69 Years
Not Enrolling

Thank you

Trial Information

S9805, Phase II Study of Tandem High Dose Melphalan Supported by Peripheral Blood Stem Cell Support in Waldenstrom's Macroglobulinemia (WM)

OBJECTIVES: I. Assess remission rates and overall and progression-free survival in patients
with Waldenstrom's macroglobulinemia treated with tandem high dose melphalan supported by
peripheral blood stem cell support. II. Assess the associated hematologic and nonhematologic
toxicities of this regimen in these patients.

OUTLINE: Regimen A (dexamethasone induction): All patients receive high dose dexamethasone
orally on days 1-4, 9-12, and 17-20; courses repeat every 35 days for a total of 3 courses.
Regimen B (stem cell mobilization and collection): Following a 4-6 week break after
dexamethasone induction and regardless of response or progression, patients have stem cells
collected following administration of filgrastim (G-CSF) by injection; G-CSF continues until
completion of stem cell collection (maximum of 6 aphereses). Regimen C (first peripheral
blood stem cell transplant (PBSCT)): Regardless of disease progression, patients recovered
from toxicities from dexamethasone induction and stem cell mobilization and collection, and
who have adequate number of CD34 cells collected for at least 1 transplant, receive 1 dose
of melphalan daily for 2 days followed by peripheral stem cell reinfusion. G-CSF is given by
injection beginning on the day after peripheral stem cell reinfusion and continues until the
absolute granulocyte count is greater than 1,000/mm3 on 3 consecutive days. Regimen D
(second PBSCT): Patients who had adequate stem cell collection for 2 transplants during
regimen B, have no evidence of disease progression after the first transplant, and have
recovered from effects of previous treatment undergo a second treatment with high dose
melphalan with PBSCT and G-CSF support, given 3-12 months following the first transplant.
Patients who had enough cells collected for only one transplant go directly to regimen E.
Regimen E (maintenance interferon alfa): Beginning 5-12 weeks after transplant and upon
hematologic recovery of blood counts and other toxicities, patients with at least a partial
response after high dose melphalan and PBSCT receive subcutaneous interferon alfa injections
3 times a week for 5 years or until disease progression, relapse, or toxicity. Patients are
followed every month for 6 months, then every 3 months for 5 years, then annually

PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study over 4 years.

Inclusion Criteria

DISEASE CHARACTERISTICS: Immunologically diagnosed Waldenstrom's macroglobulinemia (WM)
Evaluable quantifiable IgM One of the following criteria must be met: 1) Patient
demonstrates clinical symptoms such as fatigue, dizziness, visual inacuity, or hemorrhagic
manifestations of WM with anemia, hyperviscosity, thrombocytopenia, or coagulopathies 2)
Advanced tumor mass present involving ONE of the following: Extensive lymphadenopathy
(greater than 2 cm) Hepato or splenomegaly palpable on clinical examination Marked bone
marrow infiltration greater than 50% 3) Progressive disease; i.e., increase in IgM
concentration by at least 50%, and/or a drop of greater than 2 g/dL in hemoglobin (in the
absence of gastrointestinal bleeding), and/or a greater than 50,000/mm3 decrease in

PATIENT CHARACTERISTICS: Age: Under 70 Performance status: SWOG 0-2 Life expectancy: Not
specified Hematopoietic: See Disease Characteristics Hepatic: Not specified Renal: Not
specified Cardiovascular: At least 6 months since myocardial infarction No congestive
heart failure No arrhythmia refractory to therapy Ejection fraction within normal range by
MUGA or ECHO Pulmonary: FEV1 at least 50% of predicted DLCO at least 50% of predicted
Other: Not pregnant or nursing Effective contraception required of fertile patients No
significant comorbid condition No uncontrolled life-threatening infection No uncontrolled
diabetes No other malignancy within past 5 years except adequately treated basal or
squamous cell skin cancer, carcinoma in situ of the cervix or adequately treated stage I
or II cancer currently in remission HIV negative Hepatitis B surface antigen negative

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since chemotherapy and recovered Endocrine therapy: Not specified Radiotherapy: At least 4
weeks since radiotherapy and recovered Surgery: Not specified

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

confirmed remission rate

Outcome Time Frame:

until death

Safety Issue:


Principal Investigator

Madhav Dhodapkar, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Rockefeller University


United States: Federal Government

Study ID:




Start Date:

September 1998

Completion Date:

January 2004

Related Keywords:

  • Lymphoma
  • Waldenström macroglobulinemia
  • Lymphoma
  • Waldenstrom Macroglobulinemia



Arizona Cancer Center Tucson, Arizona  85724
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752
Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California  90095-1781
USC/Norris Comprehensive Cancer Center Los Angeles, California  90033-0800
University of Colorado Cancer Center Denver, Colorado  80262
Albert B. Chandler Medical Center, University of Kentucky Lexington, Kentucky  40536-0084
Barbara Ann Karmanos Cancer Institute Detroit, Michigan  48201
University of Mississippi Medical Center Jackson, Mississippi  39216-4505
Barrett Cancer Center, The University Hospital Cincinnati, Ohio  45219
Cleveland Clinic Cancer Center Cleveland, Ohio  44195
CCOP - Upstate Carolina Spartanburg, South Carolina  29303
University of California Davis Medical Center Sacramento, California  95817
CCOP - Wichita Wichita, Kansas  67214-3882
MBCCOP - LSU Medical Center New Orleans, Louisiana  70112
University of Texas Health Science Center at San Antonio San Antonio, Texas  78284-7811
CCOP - Greater Phoenix Phoenix, Arizona  85006-2726
CCOP - Atlanta Regional Atlanta, Georgia  30342-1701
CCOP - Kansas City Kansas City, Missouri  64131
UCSF Cancer Center and Cancer Research Institute San Francisco, California  94115-0128
Loyola University Medical Center Maywood, Illinois  60153
Henry Ford Hospital Detroit, Michigan  48202
Huntsman Cancer Institute Salt Lake City, Utah  84112
MBCCOP - University of South Alabama Mobile, Alabama  36688
Veterans Affairs Medical Center - Long Beach Long Beach, California  90822
Beckman Research Institute, City of Hope Los Angeles, California  91010
Veterans Affairs Outpatient Clinic - Martinez Martinez, California  94553
CCOP - Bay Area Tumor Institute Oakland, California  94609-3305
CCOP - Santa Rosa Memorial Hospital Santa Rosa, California  95403
David Grant Medical Center Travis Air Force Base, California  94535
CCOP - Central Illinois Springfield, Illinois  62526
Veterans Affairs Medical Center - Lexington Lexington, Kentucky  40511-1093
Tulane University School of Medicine New Orleans, Louisiana  70112
Veterans Affairs Medical Center - Boston (Jamaica Plain) Jamaica Plain, Massachusetts  02130
Veterans Affairs Medical Center - Ann Arbor Ann Arbor, Michigan  48105
St. Louis University Health Sciences Center Saint Louis, Missouri  63110-0250
CCOP - Cancer Research for the Ozarks Springfield, Missouri  65807
CCOP - Montana Cancer Consortium Billings, Montana  59101
CCOP - Columbus Columbus, Ohio  43206
Veterans Affairs Medical Center - Dayton Dayton, Ohio  45428
CCOP - Dayton Kettering, Ohio  45429
CCOP - Columbia River Program Portland, Oregon  97213
CCOP - Greenville Greenville, South Carolina  29615
University of Texas Medical Branch Galveston, Texas  77555-1329
Swedish Cancer Institute Seattle, Washington  98104
CCOP - Scott and White Hospital Temple, Texas  76508
Cancer Research Center of Hawaii Honolulu, Hawaii  96813
Veterans Affairs Medical Center - Tucson Tucson, Arizona  85723
University of Arkansas for Medical Sciences Little Rock, Arkansas  72205
Veterans Affairs Medical Center - Little Rock (McClellan) Little Rock, Arkansas  72205
Veterans Affairs Medical Center - Denver Denver, Colorado  80220
Dwight David Eisenhower Army Medical Center Fort Gordon, Georgia  30905-5650
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital) Hines, Illinois  60141
University of Kansas Medical Center Kansas City, Kansas  66160-7353
Veterans Affairs Medical Center - Wichita Wichita, Kansas  67218
Veterans Affairs Medical Center - Shreveport Shreveport, Louisiana  71130
Boston Medical Center Boston, Massachusetts  02118
Veterans Affairs Medical Center - Detroit Detroit, Michigan  48201-1932
Providence Hospital - Southfield Southfield, Michigan  48075-9975
Veterans Affairs Medical Center - Biloxi Biloxi, Mississippi  39531-2410
Veterans Affairs Medical Center - Jackson Jackson, Mississippi  39216
Keesler Medical Center - Keesler AFB Keesler AFB, Mississippi  39534-2576
Veterans Affairs Medical Center - Kansas City Kansas City, Missouri  64128
CCOP - St. Louis-Cape Girardeau Saint Louis, Missouri  63141
Veterans Affairs Medical Center - Albuquerque Albuquerque, New Mexico  87108-5138
Herbert Irving Comprehensive Cancer Center New York, New York  10032
Veterans Affairs Medical Center - Cincinnati Cincinnati, Ohio  45220-2288
Oklahoma Medical Research Foundation Oklahoma City, Oklahoma  73104
Veterans Affairs Medical Center - Oklahoma City Oklahoma City, Oklahoma  73104
Veterans Affairs Medical Center - Portland Portland, Oregon  97207
Brooke Army Medical Center Fort Sam Houston, Texas  78234-6200
Texas Tech University Health Science Center Lubbock, Texas  79415
Veterans Affairs Medical Center - San Antonio (Murphy) San Antonio, Texas  78284
Veterans Affairs Medical Center - Temple Temple, Texas  76504
Veterans Affairs Medical Center - Salt Lake City Salt Lake City, Utah  84148
CCOP - Virginia Mason Research Center Seattle, Washington  98101
Veterans Affairs Medical Center - Seattle Seattle, Washington  98108
CCOP - Northwest Tacoma, Washington  98405-0986
Veterans Affairs Medical Center - Phoenix (Hayden) Phoenix, Arizona  85012
Veterans Affairs Medical Center - New Orleans New Orleans, Louisiana  70112
CCOP - Grand Rapids Clinical Oncology Program Grand Rapids, Michigan  49503
Oregon Cancer Center at Oregon Health Sciences University Portland, Oregon  97201-3098
University of New Mexico Cancer Research & Treatment Center Albuquerque, New Mexico  87131
Veterans Affairs Medical Center - Brooklyn Brooklyn, New York  11209
Louisiana State University Hospital - Shreveport Shreveport, Louisiana  71130-3932